| Trial ID: | L3030 |
| Source ID: | NCT06068686
|
| Associated Drug: |
Vildagliptin 50 Mg
|
| Title: |
Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Vildagliptin 50 MG|DRUG: Glimepiride 3 Mg Oral Tablet
|
| Outcome Measures: |
Primary: Copeptin Concentration (pg/ml), Copeptin serum Level, 3 month|NT-proBNP Concentration (pg/ml), NT-proBNP serum Level, 3 Months | Secondary: Fasting blood glucose (mg/dl), Fasting Blood Glucose level, 3 month
|
| Sponsor/Collaborators: |
Sponsor: Damanhour University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
70
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-10-01
|
| Completion Date: |
2024-12-01
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-04
|
| Locations: |
Damanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes., Damanhūr, Elbehairah, 31527, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT06068686
|
